Last reviewed · How we verify

NCT03899740

Expert Statements Concerning the Tapering of Oral Corticosteroids (OCS) for the Treatment of Asthma

Status unknown Last updated 4 September 2019
What this trial tests

trial testing Brainstorming 1 in Asthma in 30 participants. Status unknown.

Timeline
1 April 2019
Primary endpoint
26 September 2019
26 September 2019

Quick facts

Lead sponsorAssociation Jean Baptiste Desbrest
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment30
Start date1 April 2019
Primary completion26 September 2019
Estimated completion26 September 2019
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Association Jean Baptiste Desbrest

Who can join

Eligibility, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objectives of this study are to use the Delphi method to assemble an expert panel representing innovation in asthma treatment, to collect freely suggested recommendation statements concerning OCS tapering (and sub-topics) among severe asthma patients from this panel for peer evaluation, and finally to determine the level of consensus for each statement from the panel as a whole.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Brainstorming 1

Trials testing the same drug.

Other recruiting trials for Asthma

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03899740.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing